stockrow
Friday 6 November 2026
Export AXGN’s income statement to Excel — free account
AxoGen, Inc.
AXGN Healthcare Medical Devices
AxoGen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $225.2 million, up 20.2% from fiscal 2024.
- Revenue
- +26.2%
- EPS
- +163.2%
- Free cash flow
- +995.0%
- Total debt
- −73.1%
Quarter to September 2026, against a year earlier
50.00
1.25
+2.56%
Follow AXGN
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
6.69 | 7.18 | 9.81 | 8.66 | |
P/FCF ratio |
0.00 | 223.17 | 378.46 | 115.48 | |
P/Operating CF |
496.12 | 1,092.16 | 341.19 | 139.83 | |
P/B ratio |
11.70 | 6.98 | 9.61 | 4.66 | |
Price to Tangible BV |
12.34 | 7.20 | 9.91 | 4.74 | |
EV/Sales |
6.79 | 6.83 | 9.44 | 7.42 | |
EV/EBITDA |
986.66 | 3,460.14 | 0.00 | 0.00 | |
EV/Operating CF |
1,883.41 | 104.54 | 157.54 | 69.88 | |
EV/FCF |
(319.81) | 212.33 | 364.14 | 98.99 | |
Quick Ratio |
3.04 | 5.07 | 4.86 | 10.54 | |
Current Ratio |
5.11 | 7.10 | 6.60 | 12.02 | |
Net Debt/EBITDA |
(3.36) | 129.83 | 23,830.25 | (107.27) | |
Debt/Assets |
30.51% | 7.13% | 5.93% | 3.21% | |
Debt/Equity |
0.52 | 0.08 | 0.07 | 0.04 | |
Asset Turnover |
1.06 | 0.98 | 0.98 | 0.70 | |
Operating CF/Net income |
(0.23) | (0.08) | (4.76) | 7.08 | |
Capex/Depreciation |
(0.61) | (1.35) | (0.81) | (0.78) | |
Interest Coverage |
(5.69) | (4.08) | (2,156.00) | 955.00 | |
Research and Development Expense of Revenue |
20.66% | 12.23% | 12.32% | 11.80% | |
Selling, General and Administrative Expense of Revenue |
69.79% | 67.53% | 63.45% | 61.75% | |
Intangible Assets out of Total Assets |
0.03 | 0.03 | 0.02 | 0.01 | |
Share Based Compensation of Revenue |
27.73% | 11.13% | 12.57% | 11.60% | |
Graham Net Nets |
0.02 | 0.08 | 0.06 | 0.17 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(1.02%) | (1.92%) | (1.46%) | (1.55%) | |
Free Cash Flow Yield |
(0.32%) | 0.45% | 0.26% | 0.87% | |
Revenue per Share |
1.30 | 1.19 | 1.31 | 1.37 | |
Operating CF per Share |
0.07 | 0.03 | 0.14 | 0.30 | |
Capex per Share |
(0.04) | (0.06) | (0.03) | (0.03) | |
Free Cash Flow per Share |
0.02 | (0.03) | 0.10 | 0.27 | |
Cash per Share |
0.99 | 2.01 | 2.13 | 6.35 | |
Shareholders Equity per Share |
2.80 | 4.75 | 4.80 | 8.99 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.80 | 4.75 | 4.80 | 8.99 | |
Free Cash Flow |
1.08 | (1.40) | 5.47 | 14.87 | |
Working Capital |
96.87 | 158.70 | 170.00 | 401.64 | |
Capital Expenditures |
(1.96) | (2.96) | (1.75) | (1.67) | |
Net Current Asset Value |
27.58 | 140.03 | 151.77 | 383.86 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.05 | 0.03 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
25.14 | 27.30 | 31.08 | 32.39 | |
Average Payables |
24.91 | 21.78 | 25.58 | 30.15 | |
Average Inventory |
37.78 | 40.79 | 42.04 | 44.82 | |
Average Assets |
212.71 | 242.83 | 255.16 | 383.37 | |
Average Common Equity |
116.38 | 175.09 | 184.27 | 308.45 |
Columns are period end dates · fundamentals updated 5 Nov 2026